NCT06159998

Withdrawn

New Markers for Treatment Response to Radiotherapy in Prosta...

University of Basel Source

Compare

Other study identifiers

Sponsor study identifier

EKBB 180/09

Secondary identifiers

180/09

OTHER · EKBB

Study Type

observational

Actual enrollment (reported)

0

Locations

1 country

Sites

1

Timeline

Study Start

July 2009

Actual (reported)

Primary Completion

July 2014

Actual (reported)

Study Completion

July 2019

Actual (reported)

Brief Summary

The actual follow-up of patients undergoing definite radiotherapy for prostate cancer includes regular measurements of prostate specific antigen (PSA). Successful radiotherapy is critically dependent on local control of cancer; however, PSA takes 2-3 years to reach a nadir after therapy. We aim at collecting blood/urine after prostate massage before, and after radiotherapy in order to define new markers predicting local control earlier and more precisely than PSA.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: July 2019
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2009
Actual (reported)
First Submitted
December 11, 2012
Actual (reported)
Primary Completion
July 2014
Actual (reported)
Study Completion
July 2019
Actual (reported)
First Posted
December 7, 2023
Actual (reported)

Last Updated: December 7, 2023
Status Verified: November 2023
Last Update Submitted: November 28, 2023

Conditions

Prostate Cancer

Keywords

radiotherapymarkers

Outcome Measures

Primary Outcomes (1)

Bio-repository
first assessment using predifined markers after recruitment of 15 patients followed for 1 year

Eligibility Criteria

Age18 Years - 85 Years

Sexmale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Men undergoing definite radiotherapy for prostate cancer.

You may qualify if:

All patients undergoing radiotherapy of biopsy confirmed clinically localised adenocarcinoma of the prostate

You may not qualify if:

Sponsors & Collaborators

University of Basel
Otherlead

Study Sites (1)

Department of Urology, University Hospital Basel

Basel, Canton of Basel-City, 4031, Switzerland

Biospecimen

Retention: SAMPLES WITH DNA

* PBMCs * Sera * Urine * prostate cells in urine

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

Cyrill A Rentsch, MD-PhD
University Hospital, Basel, Switzerland
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: MD-PhD

Study Record Dates

First Submitted

December 11, 2012

First Posted

December 7, 2023

Study Start

July 2009

Actual (reported)

NCT00913263

An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate

Phase 1/2Completed

NCT00895115

Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer

Phase 1Completed

NCT00728663

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Phase 2Completed

NCT00831792

TKI258 in Castrate Resistant Prostate Cancer

Phase 2Completed

NCT01118741

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

Not ApplicableCompleted

NCT01525914

Response of Patients on Surveillance for Prostate Cancer to Dutasteride

Completed

patients with inflammatory processes of the rectum
patients with no rectum due to previous surgery

Contact the study team to confirm eligibility.

Primary Completion

July 2014

Actual (reported)

Study Completion

July 2019

Actual (reported)

Last Updated

December 7, 2023

Record last verified: 2023-11

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06159998
Data provider: ClinicalTrials.gov
Source updated: 2023-12-07
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:18 UTC

Locations

CH(1)

Study Stopped

New Markers for Treatment Response to Radiotherapy in Prostate Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations